Navigation Links
Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents
Date:7/24/2013

COLUMBUS, Ohio -- Small proteins called peptides that consist of 10 to 50 amino acids are being studied as cancer vaccines and as possibly safer, more effective and less costly alternatives to the monoclonal-antibody-based drugs and small-molecule inhibitors now used to treat many malignancies.

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) have identified two regions on the HER1/EGFR receptor, a protein important for cancer-cell growth and metastasis and for poor patient survival, as targets for peptide agents.

The receptor molecule protrudes from the surface of cancer cells in abnormally high numbers. It is activated by growth factors in the blood and released by other cells in the tumor, stimulating tumor growth.

"Our findings could lead to novel peptide vaccines and mimetic inhibitors that target HER1 in tumors of the breast, lung, colon and head and neck, and that overcome many of the significant shortcomings of antibody-based drugs such as cetuximab," says principal investigator Pravin Kaumaya, PhD, director of the division of vaccine development at the OSUCCC - James.

"Such peptide agents might enable the development of combination immunotherapies using either HER2 vaccines or VEGF therapy that avoid the mechanisms of resistance or secondary treatment failures sometimes experienced with antibody treatment," says Kaumaya, who is also professor of obstetrics and gynecology, of molecular and cellular biochemistry, and of microbiology at Ohio State.

The study is published in the Journal of Immunology.

HER1 is a member of the epithelial growth factor (EGF) family of cell-surface receptors, which includes the HER2 receptor. These receptors play a central role in the development of a variety of human cancers, including certain breast cancers, lung cancer, colorectal and head and neck cancers.

Kaumaya and his colleagues evaluated three sequences of peptides to determine which were the most specific and immunogenic (i.e., raised the strongest immune response in test animals), and therefore were best suited for use as vaccines or therapeutics. The three sequences, or epitopes, were based on the site of contact between HER1 and the growth factor that normally binds with it, epithelial growth factor (EGF). Key technical findings included:

  • Two of the sequences (382-410 and 418-435) were identified as best for use as cancer therapy or a cancer vaccine;
  • The 382-410 epitope overlaps the binding site of cetuximab, an antibody agent that inhibits HER1 binding; however, the 418-435 epitope significantly inhibited tumor growth in transplantable breast and lung cancer models;
  • The vaccine constructs were highly immunogenic and established immunological memory in a rabbit model. "Overall," Kaumaya says, "our results show that the 418-435 epitope has great potential for use as a vaccine or treatment option for HER1-expressing cancers."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. University of Hawaii Cancer Center researchers report
2. Mount Sinai researchers discover mechanism behind development of autoimmune hepatitis
3. Dead gene comes to life, puts chill on inflammation, Stanford researchers find
4. Researchers identify 146 contemporary medical practices offering no net benefits
5. Protein complex linked to cancer growth may also help fight tumors, Moffitt researchers say
6. Disney researchers use encoded audio signals to provide second screen experiences at most venues
7. Researchers Discover a Gene That Is Associated with Obesity
8. Researchers report a complete description of gene expression in the human retina
9. Researchers Find That Setting Weight Loss Ranges Are More Beneficial than Specifics, Making Weight Loss Via Supplements Like Prescopodene More Likely
10. Single dose of ADHD drug can reduce fall risk in older adults -- Ben-Gurion U researchers
11. UCLA researchers find link between intestinal bacteria and white blood cell cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is announcing their participation ... Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in ... program. , “We know it’s easy to get carried away when you’re ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and streamline ... been condensed to a single page, maximizing usability and improving efficiency significantly for ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Attorney Robert ... fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, ... one of those children. James saw firsthand the effect of the critical funding gap ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... LONDON , Jan. 19, 2017 ... 2022 Summary GlobalData,s new report, "Germany Cataract ... data on the Germany Cataract Surgery Devices market. The ... (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares ...
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... Market? Which areas are going to grow at the ... to 2026, assessing data, trends, opportunities and prospects. ... Discover the most lucrative areas in the industry and ... assess forecasted sales across the all the major categories ...
Breaking Medicine Technology: